Skip to main content
bioRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search
New Results

New mechanism-based inhibitors of aspartate transcarbamoylase for anticancer drug development

Zhen Lei, Nan Wang, Biying Wang, Zhifang Lu, Hongwei Tan, View ORCID ProfileJimin Zheng, View ORCID ProfileZongchao Jia
doi: https://doi.org/10.1101/662718
Zhen Lei
1College of Chemistry, Beijing Normal University, Beijing, 100875, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nan Wang
1College of Chemistry, Beijing Normal University, Beijing, 100875, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Biying Wang
1College of Chemistry, Beijing Normal University, Beijing, 100875, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhifang Lu
1College of Chemistry, Beijing Normal University, Beijing, 100875, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hongwei Tan
1College of Chemistry, Beijing Normal University, Beijing, 100875, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jimin Zheng
1College of Chemistry, Beijing Normal University, Beijing, 100875, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jimin Zheng
  • For correspondence: jimin_z@bnu.edu.cn jia@queensu.ca
Zongchao Jia
2Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, Ontario, K7L3N6, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Zongchao Jia
  • For correspondence: jimin_z@bnu.edu.cn jia@queensu.ca
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Preview PDF
Loading

Abstract

Aspartate transcarbamoylase (ATCase) is a key enzyme which regulates and catalyzes the second step of de novo pyrimidine synthesis in all organisms. E. coli ATCase is a prototypic enzyme regulated by both product feedback and substrate cooperativity, whereas human ATCase is a potential anticancer target. Through structural and biochemical analyses, we revealed that R167/130’s loop region in ATCase serves as a gatekeeper for the active site, playing a new and unappreciated role in feedback regulation. Based on virtual compound screening simultaneously targeting the new regulatory region and active site of human ATCase, two compounds were identified to exhibit strong inhibition of ATCase activity, proliferation of multiple cancer cell lines, and growth of xenograft tumors. Our work has not only revealed a previously unknown regulatory region of ATCase that helps explain feedback regulation, but also successfully guided the identification of new ATCase inhibitors for anticancer drug development using a dual-targeting strategy.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted June 06, 2019.
Download PDF
Email

Thank you for your interest in spreading the word about bioRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
New mechanism-based inhibitors of aspartate transcarbamoylase for anticancer drug development
(Your Name) has forwarded a page to you from bioRxiv
(Your Name) thought you would like to see this page from the bioRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
New mechanism-based inhibitors of aspartate transcarbamoylase for anticancer drug development
Zhen Lei, Nan Wang, Biying Wang, Zhifang Lu, Hongwei Tan, Jimin Zheng, Zongchao Jia
bioRxiv 662718; doi: https://doi.org/10.1101/662718
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
New mechanism-based inhibitors of aspartate transcarbamoylase for anticancer drug development
Zhen Lei, Nan Wang, Biying Wang, Zhifang Lu, Hongwei Tan, Jimin Zheng, Zongchao Jia
bioRxiv 662718; doi: https://doi.org/10.1101/662718

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Cancer Biology
Subject Areas
All Articles
  • Animal Behavior and Cognition (3707)
  • Biochemistry (7835)
  • Bioengineering (5709)
  • Bioinformatics (21372)
  • Biophysics (10616)
  • Cancer Biology (8218)
  • Cell Biology (11990)
  • Clinical Trials (138)
  • Developmental Biology (6794)
  • Ecology (10435)
  • Epidemiology (2065)
  • Evolutionary Biology (13920)
  • Genetics (9736)
  • Genomics (13119)
  • Immunology (8183)
  • Microbiology (20092)
  • Molecular Biology (7886)
  • Neuroscience (43219)
  • Paleontology (322)
  • Pathology (1285)
  • Pharmacology and Toxicology (2270)
  • Physiology (3367)
  • Plant Biology (7263)
  • Scientific Communication and Education (1317)
  • Synthetic Biology (2012)
  • Systems Biology (5554)
  • Zoology (1136)